Description: This State-of-the-Art session provides a timely update on the evolving MASLD therapies pipeline, featuring insights into emerging pharmacologic agents and real-world data on current treatments. Topics include the impact of SGLT-2 and GLP-1 receptor agonists on cirrhosis outcomes, eligibility criteria for resmetirom therapy, and phase 2 results for efimosfermin alfa in MASH with fibrosis.
Moderator(s): Meena B Bansal (Icahn School of Medicine at Mount Sinai) Bilal Hameed (University of California, San Francisco)
Learning Objectives: • Describe the impact of SGLT-2 and GLP-1 receptor agonists on cirrhosis outcomes • Identify the eligibility criteria for resmetirom therapy • Discuss phase 2 results for efimosfermin alfa in MASH with fibrosis
